3,3-dibenzyl-8-isopropoxyimidazo(1,2-a)pyridin-2(3H)-one | 324077-53-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 3,3-dibenzyl-8-isopropoxyimidazo(1,2-a)pyridin-2(3H)-one
• 英文别名: 3,3-Dibenzyl-8-isopropoxyimidazo[1,2-a]-pyridin-2(3H)-one；3,3-dibenzyl-8-propan-2-yloxyimidazo[1,2-a]pyridin-2-one
• CAS: 324077-53-4
• 化学式: C₂₄H₂₄N₂O₂
• 分子量: 372.467
• InChiKey: FNKWJGNREXOULD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  41.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-amino-3-isopropoxy-1-(ethoxy-carbonylmethyl) pyridiniumbromide 、 溴甲苯 在 乙醇 、 sodium 作用下， 反应 5.0h， 以92%的产率得到3,3-dibenzyl-8-isopropoxyimidazo(1,2-a)pyridin-2(3H)-one
  参考文献：
  名称：

  METHODS FOR TREATING DEPRESSION, NEURODEGENERATION, INHIBITING AMYLOID BETA DEPOSITION, DELAYING SENESCENCE, AND EXTENDING LIFE SPANS WITH HETEROCYCLIC COMPOUNDS

  摘要：

  揭示了一种抗抑郁剂、神经保护剂、淀粉样蛋白β沉积抑制剂或延缓衰老的组合物，其中包含具有通用式(I)的杂环化合物。

  公开号：

  US20080103157A1

文献信息

• METHOD OF TREATING COGNITIVE IMPAIRMENT
  申请人：YAMAGUCHI Yoshimasa

  公开号：US20090221554A1

  公开（公告）日：2009-09-03

  Disclosed is an method of treating cognitive impairment, including administering to a subject in need thereof a combination of a therapeutic agent for neurodegenerative disease and a therapeutically effective amount of a heterocyclic compound represented by the following general formula (I):

  本发明揭示了一种治疗认知障碍的方法，包括向需要治疗的受试者施用一种神经退行性疾病治疗剂和一种由以下一般式(I)表示的杂环化合物的治疗有效量的组合物。
• Azaindolizinone derivatives and cerebral function improvers containing the same as the active ingredient
  申请人：Zenyaku Kogyo Kabushiki Kaisha

  公开号：US06635652B1

  公开（公告）日：2003-10-21

  Azaindolizinon derivatives or pharmaceutically acceptable salts thereof represented by the formula I: wherein R1 represents hydrogen atom, halogen atom or C1-C6 alkyl, R2 represents hydrogen atom, C1-C6 alkyl, C1-C6alkoxy, hydroxy, halogen atom, amino, acetylamino, benzylamino, trifluoromethyl or —O—(CH2)n—R5 (R5 represents vinyl, C3-C8 cycloalkyl or phenyl, n being 0 or 1), R3 and R4 respectively represent C1-C6 alkyl or —CH(R7)—R6 (wherein R6 represents vinyl, ethynyl, phenyl (which may be substituted with C1-C6 alkyl, C1-C6 alkoxy, hydroxy, one or two halogen atoms, di C1-C6 alkylamino, cyano, nitro, carboxy or phenyl), phenethyl, pyridyl, thienyl or furyl and R7 represents hydrogen atom or C1-C6 alkyl) or R3 is coupled with R4 to form indan or dihydrophenalene.

  式I所示的Azaindolizinon衍生物或其药学上可接受的盐，其中R1代表氢原子、卤素原子或C1-C6烷基，R2代表氢原子、C1-C6烷基、C1-C6烷氧基、羟基、卤素原子、氨基、乙酰氨基、苄基氨基、三氟甲基或—O—(CH2)n—R5（其中R5代表乙烯基、C3-C8环烷基或苯基，n为0或1），R3和R4分别代表C1-C6烷基或—CH(R7)—R6（其中R6代表乙烯基、乙炔基、苯基（可以被C1-C6烷基、C1-C6烷氧基、羟基、一个或两个卤素原子、二个C1-C6烷基氨基、氰基、硝基、羧基或苯基取代），苯乙基、吡啶基、噻吩基或呋喃基，R7代表氢原子或C1-C6烷基），或R3与R4结合形成茚烷或二氢茚烯。
• Method of Treating Cognitive Impairment
  申请人：WEBER Eckard

  公开号：US20100256173A1

  公开（公告）日：2010-10-07

  This invention relates to the treatment and prevention of cognitive impairment, and particularly to the treatment and prevention of cognitive impairment caused by or associated with Huntington's Disease, Lewy Body Dementia, Pick's Disease and Down's Syndrome.

  本发明涉及治疗和预防认知障碍，特别是治疗和预防由亨廷顿病、路易体痴呆、皮克氏病和唐氏综合症引起或相关的认知障碍。
• Method of Inducing Cleavage of Amyloid Precursor Protein to Form a Novel Fragment
  申请人：Green Kim Nicholas

  公开号：US20100168135A1

  公开（公告）日：2010-07-01

  The present invention provides a method of inducing cleavage of amyloid precursor protein to produce an approximately 17 kilodalton carboxy-terminal fragment of amyloid precursor protein in a subject, the method comprising administering a heterocyclic compound or a pharmaceutically acceptable salt, hydrate or prodrug thereof to a subject in need thereof, wherein the approximately 17 kilodalton fragment includes the carboxyterminal amino acid sequence of amyloid precursor protein and amyloid-beta amino acid sequence. Also provided is a screening method for identifying compounds induce cleavage of amyloid precursor protein to produce the approximately 17 kilodalton carboxy-terminal fragment of amyloid precursor protein.

  本发明提供了一种诱导淀粉样前体蛋白裂解以产生约17千道顿的淀粉样前体蛋白羧基末端片段的方法，其中该方法包括向需要该方法的受体中给予杂环化合物或其药学上可接受的盐、水合物或前药，其中约17千道顿的片段包括淀粉样前体蛋白羧基末端氨基酸序列和淀粉样β氨基酸序列。还提供了一种筛选诱导淀粉样前体蛋白裂解以产生约17千道顿淀粉样前体蛋白羧基末端片段的化合物的方法。
• AZAINDOLIZINONE DERIVATIVES AND CEREBRAL FUNCTION IMPROVERS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
  申请人：ZENYAKU KOGYO KABUSHIKI KAISHA

  公开号：EP1219621A1

  公开（公告）日：2002-07-03

  Azaindolizinon derivatives or pharmaceutically acceptable salts thereof represented by the formula I: wherein R1 represents hydrogen atom, halogen atom or C1-C6 alkyl, R2 represents hydrogen atom, C1-C6 alkyl, C1-C6alkoxy, hydroxy, halogen atom, amino, acetylamino, benzylamino, trifluoromethyl or -O-(CH2)n-R5 (R5 represents vinyl, C3-C8 cycloalkyl or phenyl, n being 0 or 1), R3 and R4 respectively represent C1-C6 alkyl or -CH(R7)-R6 (wherein R6 represents vinyl, ethynyl, phenyl (which may be substituted with C1-C6 alkyl, C1-C6 alkoxy, hydroxy, one or two halogen atoms, di C1-C6 alkylamino, cyano, nitro, carboxy or phenyl), phenethyl, pyridyl, thienyl or furyl and R7 represents hydrogen atom or C1-C6 alkyl) or R3 is coupled with R4 to form indan or dihydrophenalene.

  由式 I 代表的氮杂环戊烯嗪酮衍生物或其药学上可接受的盐： 其中 R1 代表氢原子、卤素原子或 C1-C6 烷基、 R2代表氢原子、C1-C6烷基、C1-C6烷氧基、羟基、卤素原子、氨基、乙酰氨基、苄基氨基、三氟甲基或-O-(CH2)n-R5（R5代表乙烯基、C3-C8环烷基或苯基，n为0或1）、 R3和R4分别代表C1-C6烷基或-CH(R7)-R6（其中R6代表乙烯基、乙炔基、苯基（可被C1-C6烷基、C1-C6烷氧基、羟基、一个或两个卤素原子、二C1-C6烷基氨基、氰基、硝基、羧基或苯基取代）、苯乙基、吡啶基、噻吩基或呋喃基，R7代表氢原子或C1-C6烷基），或R3与R4偶联形成茚或二氢苯丙烯。